Vascular permeability factor (VPF) is an Mr 40-kD protein that has been purified from the conditioned medium of guinea pig line 10 tumor cells grown in vitro, and increases fluid permeability from blood vessels when injected intradermally. Addition of VPF to cultures of vascular endothelial cells in vitro unexpectedly stimulated cellular proliferation. VPF promoted the growth of new blood vessels when administered into healing rabbit bone grafts or rat corneas. The identity of the growth factor activity with VPF was established in four ways: (a) the molecular weight of the activity in preparative SDS-PAGE was the same as VPF (M, 40 kD); (b) multiple isoforms (pI 2 8) for both VPF and the growth-promoting activity were observed; (c) a single, unique NH2-terminal amino acid sequence was obtained; (d) both growth factor and permeabilityenhancing activities were immunoadsorbed using antipeptide IgG that recognized the amino terminus of VPF. Furthermore,
Introduction
The observation that blood vessels in and around tumors display increased permeability toward plasma fluid and proteins (1) (2) (3) (4) has led to the thesis that tumor cells secrete factors that act to increase vessel permeability (5) . In support ofthis idea, a vascular permeability factor (VPF)1 was identified and puri- 1 . Abbreviations used in this paper: BAE, bovine aortic endothelial cells; EGF, epidermal growth factor; FBS, fetal bovine serum; FGF, fibroblast growth factor; HUE, human umbilical vein endothelial cells; NEpHGE, nonequilibrium pH gradient electrophoresis; PDGF, platelet-derived growth factor; TGF, transforming growth factor; TNF, tumor necrosis factor; VPF, vascular permeability factor. fied from the conditioned medium ofguinea pig line 10 tumor cells grown in vitro (6, 7, 7a) . The NH2-terminal amino acid sequence of VPF has been shown to be unrelated to other proteins for which sequence information is available, including those other proteins that are known to affect vessel permeability (7a). That the unique sequence was VPF associated was confirmed by experiments using antipeptide antibodies to block permeability enhancement (7a). The physiological relevance of VPF was suggested in experiments using antibody prepared against the Mr 34-42-kD protein that inhibited ascites fluid accumulation in tumor-bearing guinea pigs (6) . Although the physical and pharmacological properties of VPF suggested that its action was distinct from other known vasoactive agents such as bradykinin, leukokinins, plasma kallikrein, complement factors C3a or CSa, histamine or prostaglandins, the mechanism of VPF-mediated permeability enhancement is not known. VPF did not degranulate mast cells. Its action was rapid (within 5 min) and transient (diminished by 20 min), and endothelium was not damaged. VPFs with similar immunocross-reactivity have been detected in conditioned media from a variety of human and rodent tumor cell lines (8) .
The purpose of this study was to determine the direct effects of VPF on endothelial cells. The results reported here demonstrate that VPF is a specific growth factor for vascular endothelial cells in culture, that VPF binds with high affinity to an endothelial cell surface protein, possibly a VPF receptor, and that VPF promotes blood vessel growth in vivo. Methods VPFpurification. VPF was purified from cultures ofguinea pig line 10 tumor cells (6, 7, 7a) . Cells were grown in large scale suspension culture in DME with 10% FCS. Cells were resuspended in serum-free medium for 48 h, and the medium chromatographed on a column of heparinSepharose (Pharmacia Fine Chemicals, Piscataway, NJ) essentially as described in reference 6. The Miles assay (9) was used to assay activity. Active fractions were dialyzed against 0.01 M sodium phosphate (pH 6.1), loaded onto a SP-5-PW cation exchange column and eluted with a gradient of sodium chloride. Active fractions were then chromatographed on C4 and C1,8 reverse-phase HPLC columns using gradients of acetonitrile in 0.1% (vol/vol) trifluoroacetic acid (7a).
Cell culture. Bovine aortic endothelial (BAE) cells (clone JVOI 7A) and bovine smooth muscle cells (clone FCSM9) were isolated as described (10) and were grown in DME plus 10% calf serum. Bovine chondrocytes (INT) were isolated by collagenase digestion of calf cartilage and grown in DME plus 10% fetal bovine serum (FBS). Mouse fibroblasts (Balb/3T3) grown in DME plus 10% calf serum and human fetal lung fibroblasts (W 138) and mouse meyelomonocytes (WEHI-3), each grown in DME plus 10% fetal bovine serum were from the American Type Culture Collection (Rockville, MD). Human peripheral lymphocytes (GM892) grown in DME plus 10% fetal bovine serum were from the Genetic Mutant Cell Repository, The Institute for Medical Research, Camden, NJ. Human umbilical vein endothelial (HUE) cells were isolated by published procedures (11, 12) , established in MCDB1 31 medium (13) , and subcultured in MCDB 107 medium (14) supplemented with 10% FBS, 90 Mg/mI Na heparin, 30 Mg/ml Endothelial Cell Growth Supplement (Collaborative Research Inc., Lexington, MA), 10 ng/ml epidermal growth factor (EGF), 1 gg/ml hydrocortisone on human fibronectin-coated tissue culture vessels.
Rabbit bone angiogenesis assay. Angiogenesis was monitored in a healing bone graft model (15) . New Zealand white rabbits received autologous bone grafts from the iliac crest (donor site) to the mandibular body (recipient site). Blocks of cortical bone from the ileum (1 X 1 cm) were split into two 0.5 X 1 cm segments, the central cancellous areas were removed, and the cortex perforated multiple times to provide pores. 14-d sustained-release osmotic pumps (model M-2001; Alza Corp., Palo Alto, CA) were loaded with either 0.24 ml sterile saline containing 75 fg VPF and 0.1% (wt/vol) rabbit serum albumin or the albumin solution (vehicle) alone. The end of the tubing was perforated with a needle to provide multiple outlet points and placed into a channel in the bone, and the graft was placed into the recipient site in the mandible. Each animal received an experimental graft with VPF infusion, and a contralateral graft with infusion of vehicle alone. After 14 d, the blood vessels of the head were cleared by perfusion through the carotid arteries with heparinized saline. The vessels were then perfused with the orange silicone rubber compound Microfil (Canton Biomedical, Boulder, CO). After fixation, dehydration, and clearing in methysalicylate, grafts were cut in half and visualized microscopically.
Rat cornea angiogenesis assay. The rat cornea angiogenesis assay was performed as described (16) by Dr. S. Joseph Leibovich, Northwestern University (Chicago, IL). VPF (4.2 Mg) was lyophilized in the presence of 100 Mg BSA, resuspended in water at appropriate dilutions, and mixed with equal volumes of Hydron solution. Droplets of the sample/Hydron mixtures (10 Ml) were placed on the cut ends of 2-mm-diam Teflon dowels for 1 h. The resultant pellets were cut into two, each pellet thus being of defined size. Identical pellets to serve as controls were prepared from 100 Mg albumin alone, which was lyophilized and diluted as with the VPF/albumin preparation. Corneal pockets were prepared in anesthetized Wistar F233 rats, and a pellet inserted in each pocket. After 7 d, animals were perfused intraarterially with colloidal carbon and the corneas were fixed and photographed.
NHrterminal amino acid sequence analysis. Automated Edman degradation was performed with a gas phase sequencer and PTH analyzer (models 470A and 120A, respectively; Applied Biosystems, Inc., Foster City, CA). Computer searches were performed using a "fast a" program to probe National Biomedical Research Foundation (Bethesda, MD) and Genbank protein sequence data bases.
Antipeptide antibodies and immunoadsorption. A peptide corresponding to the 2 1-amino acid NH2-terminal sequence of guinea pig VPF was synthesized by conventional automated solid-phase peptide synthesis and purified using rapid-phase-(RP)-HPLC (7a). Amino acid analysis was used to confirm the identity of this peptide that consisted of the following sequence:
A PMA EGEQKPRE V V KFMD VYK 5 10 15 20
The peptide was conjugated to thyroglobulin using glutaraldehyde, and used for immunization ofrabbits. The antiserum used in this study (rabbit F003) had a 50% dilution titer of 1:3,000-5,000 in a VPF ELISA, and blocked activity in the Miles assay at a dilution of 1:500. 
Results
Effect of VPF on endothelial cell growth in vitro. Guinea pig VPF was purified from serum-free line 10 tumor cell-conditioned medium using heparin-Sepharose chromatography, cation exchange HPLC, C4 HPLC, and C18 HPLC (6, 7, 7a). The yield was -I ,g of VPF per liter of conditioned medium. Fractions from the final reverse-phase HPLC column that displayed activity in the Miles permeability assay (9) contained a closely spaced group of protein bands of M, 38-40 kD when analyzed in nonreducing gels by SDS-PAGE and silver staining ( Fig. 1 A) . In reducing gels, VPF migrated as Mr 20-and 24-kD subunits (not shown). These results confirm those of Senger et al. (6, 7a) who showed both by staining and by activity measurements that nonreduced VPF is an Mr = 34-42 kD protein. Fig. 1 B shows a Miles assay in which different amounts of VPF were injected intradermally into a guinea pig, thereby causing leakage of Evan's blue dye from nearby blood vessels into the tissues as evidenced by the presence of blue spots at the sites of injection. Increased permeability was observed with as little as 1 nM (8 ng) VPF. In experiments in which purified VPF was added to cultures of BAE cells, cell number increased in response to VPF. To determine ifthis mitogenic activity was due to VPF, a preparation was subjected to SDS-PAGE, gel slices extracted, and the extract assayed for growth-promoting activity. Fig. 1 C shows that the growth promoting activity was restricted to the Mr 40 kD fraction and coincided both with the band in the silver-stained gel and with the permeability-enhancing activity (assay not shown). This is in contrast with the heparin-binding FGFs that are endothelial cell mitogens of lower molecular weight (21). Both activities appear to be assoVascular Permeability Factor, Endothelial Cell Growth, and Angiogenesis 1471 was subjected to nonreducing SDS-PAGE using a 10% gel (18) (Fig. 3 B) , VPF mipreparation of VPF was incubated with immunoadsorbants grated as multiple-subunit bands between -Mr 18 and 24 kD. that were prepared using protein A-Sepharose that had been Note that it has been previously shown that all of the size preincubated with either antipeptide serum or anti-FBS serum forms of purified VPF in both reduced and nonreduced Westas control. Different dilutions of the supernatant were then ern blots are recognized by antipeptide antibody, and thus added to BAE cell cultures and assayed for proliferative activ-contain the same NH2-terminal sequence. The basic isoelectric ity (Fig. 2) . The control immunoadsorbant removed a portion point of the VPF isoforms are consistent with the ability of of the activity, as evidenced by displacement of the dose-re-VPF to bind tightly to a cation exchange column at pH 7.0 sponse curve toward higher concentrations, but treatment with during purification. To determine if the various isoforms observed in the silver-stained gels were biologically active, VPF was subjected to preparative NEpHGE. The gels were fractionated and extracted, and each fraction assayed for both Miles permeability activity and growth promoting activity toward BAE cells. tures of BAE cells in DME/lIO% calf serum. Cell number was determined after 5 d. Exposure to 0.5-10 ng/ml VPF increased cell numbers in growth experiments by two-to threefold with a half-maximal growth stimulation observed at -2 ng/ml (5 X 10-" M) VPF. Confluent cultures of BAE cells in serumfree DME were used for determination of The cellular specificity of the VPF-associated mitogenic activity was examined by comparing the [3H]thymidine incorporation by various cell types in serum-free medium supplemented with VPF to that obtained in serum-supplemented medium (Fig. 6) . In this experiment, all cells were deprived of serum for 24 h, then exposed for 24 h to either DME alone, DME containing excess VPF or DME containing 10% serum. As shown in Fig. 6 (26), which have been shown to stimulate several of the cell types studied here in addition to endothelial cells. Thus, unlike other growth factors, the mitogenic effect of VPF appears to be specific for vascular endothelial cells.
Because it was found that endothelial cell growth factor activity was associated with VPF, it was of interest to determine whether other factors, particularly those which affect endothelial cells, exhibited VPF-like activity. EGF (0.1-1,000 ng/ml), bFGF (0.4-400 ng/ml), aFGF (5-50 ng/ml), ILl (0.08-80 ng/ml), TGF 1 (75-12,500 ng/ml), TNF ( 102_106 ng/ml), and PDGF (6-6,000 ng/ml) were tested in the Miles assay but none of these factors caused visible vessel leakage over the concentration ranges and during the time period tested (5-15 min after injection). IL2 (3-300 ng/ml) produced a visible but significantly less intense response than VPF, confirming other observations that IL2 can enhance vascular permeability (27, 28). However, IL2, at Mr = 17,000 D (29) , has a _ Control 1 10% Serum 3 VPF Figure 6 . Cellular specificity of VPF-associated growth factor activity. Confluent cultures of cells were deprived of serum for 24 h, at which time either fresh medium alone or medium supplemented with either 10% calf serum or VPF (500 ng/ml) was added. After an additional 24 h, [3H]thymidine was added to all cultures, and incorporation into acid precipitable counts determined after 2 more h. Each bar represents the mean ± the range of duplicate determinations. The data are representative of two experiments. different molecular weight from VPF (Mr -40 kD). Furthermore, the NH2-terminal sequence for the first 36 amino acids of VPF is also distinct from IL2 (29) and other known proteins. Conversely, histamine, bradykinin, and serotonin, which are mediators of vessel permeability (30) had no effect on cell growth when added to cultures of BAE cells at concentrations between 10-10 and l0-s M. Positive controls with VPF produced two-to threefold increases in cell number.
Binding of'25I-VPF to endothelial cells. To detect the presence of specific cell surface receptors for VPF on endothelial cells, purified VPF was labeled with 125I, incubated at 40C with human umbilical vein endothelial cells (HUE cells) at a concentration of 1 nM and then treated with the chemical crosslinking reagent disuccinimidyl suberate (DSS). Samples were then analyzed by SDS-PAGE and autoradiography. Effect of VPF on angiogenesis in healing bone grafts. Because VPF appeared to be a specific endothelial cell mitogen, it seemed possible that VPF might also promote angiogenesis in vivo. To test this, VPF was administered via osmotic pumps over a 14.d period into healing mandibular bone grafts in rabbits (1'5) . Fig. 8 shows representative sections containing silicone-preserved blood vessels from contralateral control and VPF treated bone grafts from the same animal. The VPFtreated grafts clearly have more blood vessels, particularly toward the center of the grafts near the outlet of the tubing leading from the pump. This effect was seen in three out of four rabbits.
Effect of VPF on angiogenesis in the rat cornea. VPF was tested at doses between 0.4 ng and 1 gg in a rat cornea angiogenesis assay. Angiogenesis was absent in corneas receiving albumin alone, or at VPF doses of0.4 and 2 ng. Fig. 9 shows a positive angiogenic response from one oftwo corneas receiving an implant containing 20 ng VPF. A similar but stronger response was observed in two of two animals receiving 200 ng VPF. The corneas were clear, indicating the absence of significant inflammation. This was confirmed by histological examination of corneal sections in which few neutrophils or other inflammatory cells were noted. In contrast, implants containing 1 Mg VPF produced an intense angiogenic response, which was accompanied by marked clouding of the cornea, indicating inflammation. Thus, the lower'doses of VPF induced angiogenesis in the cornea without evidence of inflammation whereas at a higher dose, VPF was inflammatory.
Discussion
These data demonstrate that purified VPF can interact directly with endothelial cells in vitro and that administration of VPF in vivo results in angiogenic responses in two different model systems. The action of VPF may be mediated by the putative high-affinity VPF receptor identified here in chemical crosslinking experiments. This interaction was highly specific in that a variety of other growth factors and vasoactive agents did not affect binding. It remains to be determined, however, whether or not the vascular leakage or angiogenic responses observed in vivo in response to VPF are due entirely to direct action of VPF on endothelial cells, or if other secondary effectors are also involved. One'such secondary effector could be fibrin, which has been shown to be angiogenic, and which could be deposited at sites of VPF-mediated extravasation of fibrinogen (33) .
The mitogenic activity discovered in association with VPF was unexpected. In light ofthe extensive structural heterogeneity observed for VPF in one-and two-dimensional electrophoretic systems, and in the chromatographic systems used during purification, it was extremely important to determine if both activities emanated from the protein identified as VPF and not Vascular Permeability Factor, Endothelial Cell Growth, and Angiogenesis 1475 from a contaminant. Several lines of evidence lead to the conclusion that VPF itself is the mitogen in these preparations. First, the preparations ofVPF used in these studies were highly purified, and estimated to be > 90% pure by SDS-PAGE and silver staining. Because extremely low concentrations of VPF (-10-12 M) were needed to elicit [3H]thymidine incorporation by the endothelial cells, a contaminant present in lower concentrations would be even more potent than this. Although not impossible, such a factor has not been previously described. Secondly, both activities have molecular masses of -40 kD as determined by preparative SDS-PAGE, substantially different from most of the previously described endothelial cell mitogens (21). Thirdly, multiple isoforms of VPF were observed with apparent pls 2 8. Both types of activity were observed to be associated with all of the isoforms extracted after preparative NEpHGE. Thus, not only did the two activities have the same molecular weight, but they also had the same disperse charge properties. Fourth, sequence analysis revealed only the presence ofthe VPF sequence that is unrelated to other known growth factors or permeability enhancers (7a). Fifth, immunoadsorbtion using antipeptide IgG directed against the NH2 terminus of VPF removed both activities. This experiment most strongly suggests that both activities emanate from proteins sharing the same NH2 terminal amino acid sequence, and therefore almost certainly from the protein identified as VPF.
VPF as prepared from large-scale cultures ofguinea pig line 10 cells, is a physically heterogeneous protein. Several sized bands of -Mr 38-40 kD were observed in SDS-PAGE, and several isoforms with pls 2 8 were observed in NEpHGE. The available evidence suggests that native VPF is a dimer composed of disulfide-linked subunits, each with the same NH2-terminal amino acid sequence (7a). This conclusion is derived from the sequencing of intact VPF, in which only one se- quence is obtained, from sequencing the subunits individually (7a), and from reaction of the subunits with antipeptide antibodies in Western blots (7a). The subunits, however, vary in size from -M, 18 to 24 kD. Sequencing did reveal that -30% of the VPF molecules in some preparations were missing the first or first three amino acids. This modification could not account for the size or charge heterogeneity (the first three amino acids are neutral). Thus, the physical differences in size and charge among the forms of VPF are at present unexplained, but could arise from alternate glycosylation, proteolysis, or other modifications in parts of the VPF molecule other than the NH2 terminus. All of the isoforms had both permeability-enhancing and growth-promoting activities, but it is not known if all the forms are equipotent.
The production of angiogenic factors by various tumors has been extensively described (21, 34), but it is important to point out that VPF appears to be distinct from any of these previously described factors. The NH2-terminal sequence of VPF is also distinct from the recently described endothelial cell PDGF (35). Because VPF has been shown to be secreted by a wide variety of tumor cell types (8) , it is possible that VPF might itself serve to stimulate vessel growth towards tumors in vivo.
Presently, there is no evidence to link VPF with inflammation. However, it is interesting to note that two of the known biological activities of VPF, namely vascular permeability enhancement and promotion of neovascularization, are also often associated with inflammation. One ofthe major components of the inflammatory response is an increase in vascular permeability (36) . Endothelial cell proliferation and neovascularization also may accompany inflammation (37). Thus, both ofthe activities ofVPF make it a candidate to be an inflammatory mediator. This hypothesis is under investigation. It will be of interest to determine what role, if any, VPF might play in these processes and if VPF might play a role in related phenomena such as wound healing.
